CTOs on the Move

Valley Health Care System

www.valleyhealthcolumbus.com

 
Valley Health Care System is a Columbus, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Light Sciences Oncology

Light Sciences Oncology Inc. is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JECT

Ject is a company that specializes in medical grade skincare treatments for people who want to look their best, and who prioritize prevention, proper maintenance and a lot of self love.

Balboa Park

Balboa Park is a San Diego must-see, just minutes from downtown. The Park is home to 15 major museums, several performing arts venues, lovely gardens and many other cultural and recreational attractions–including the San Diego Zoo. Step into the beauty...

New Chapter

New Chapter, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. New Chapter, Inc. is based in Brattleboro, VT. You can find more information on New Chapter, Inc. at www.new-chapter.com

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.